[go: up one dir, main page]

AR030737A1 - Metodo de anticoncepcion y forma de administracion del mismo - Google Patents

Metodo de anticoncepcion y forma de administracion del mismo

Info

Publication number
AR030737A1
AR030737A1 ARP010104361A ARP010104361A AR030737A1 AR 030737 A1 AR030737 A1 AR 030737A1 AR P010104361 A ARP010104361 A AR P010104361A AR P010104361 A ARP010104361 A AR P010104361A AR 030737 A1 AR030737 A1 AR 030737A1
Authority
AR
Argentina
Prior art keywords
intake
administration
duration
intakes
period
Prior art date
Application number
ARP010104361A
Other languages
English (en)
Inventor
Kulmann Hermann Dr
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of AR030737A1 publication Critical patent/AR030737A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Un método para la anticoncepcion hormonal, que consta de una pluralidad de períodos de ingesta ligados entre sí, sustancialmente ilimitados en el tiempo, y que optativamente presentan una secuencia que se extiende por varios anos y que en cada caso comprende por lo menos un ciclo de ingesta, con una fase de ingesta de duracion constante que dura varios días dentro de dicho período de ingesta particular, y una pausa entre ingestas que dura varios días. En la o las fases de ingesta, la administracion diaria consiste de una unidad diaria que contiene por lo menos un componente hormonal de accion anticonceptiva, tal como un estrogeno y/o gestágeno. En la o las pausas entre ingestas, la administracion consiste ya sea de placebos libres de todo componente hormonal o bien, la pausa entre ingestas particular permanece completamente libre de administracion alguna. La duracion de la o las fases de ingesta de por lo menos el ultimo período de ingesta dura por lo menos 22 días. La o las fases de ingesta están caracterizadas porque la duracion de las mismas en cualquier período de ingesta que precede a un siguiente período de ingesta es menor que la duracion, en cada caso, de dicho período de ingesta siguiente. También se describe una forma de administracion para una anticoncepcion hormonal y, en particular, para aplicar dicho método.
ARP010104361A 2000-09-14 2001-09-14 Metodo de anticoncepcion y forma de administracion del mismo AR030737A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10045380A DE10045380A1 (de) 2000-09-14 2000-09-14 Verfahren zur Kontrazeption und dessen Darreichungsform

Publications (1)

Publication Number Publication Date
AR030737A1 true AR030737A1 (es) 2003-09-03

Family

ID=7656125

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010104361A AR030737A1 (es) 2000-09-14 2001-09-14 Metodo de anticoncepcion y forma de administracion del mismo

Country Status (31)

Country Link
US (2) US8076317B2 (es)
EP (2) EP2153849A3 (es)
JP (3) JP2004508398A (es)
KR (3) KR20090033502A (es)
CN (1) CN100560132C (es)
AR (1) AR030737A1 (es)
AT (1) ATE447972T1 (es)
AU (2) AU2001284052B2 (es)
BG (2) BG107625A (es)
BR (1) BR0113902A (es)
CA (1) CA2420292C (es)
CZ (1) CZ2003723A3 (es)
DE (2) DE10045380A1 (es)
EA (1) EA006875B1 (es)
EE (1) EE200300103A (es)
HR (1) HRP20030294A2 (es)
HU (1) HUP0301042A3 (es)
IL (2) IL154521A0 (es)
ME (1) ME00291B (es)
MX (1) MXPA03002070A (es)
NO (1) NO20031152L (es)
NZ (1) NZ524448A (es)
PE (1) PE20020425A1 (es)
PL (1) PL361161A1 (es)
SK (1) SK3102003A3 (es)
TW (1) TWI297271B (es)
UA (1) UA93650C2 (es)
UY (1) UY26932A1 (es)
WO (1) WO2002022110A2 (es)
YU (1) YU19003A (es)
ZA (1) ZA200301359B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004019743B4 (de) 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens
AU2011226911B2 (en) * 2004-04-30 2014-06-19 Bayer Intellectual Property Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
MY151322A (en) * 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
DE102004026670A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
DE102004026679A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
DE102004026671A1 (de) 2004-05-28 2005-12-15 Grünenthal GmbH Darreichungsform zur hormonalen Kontrazeption
DE102004026669A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Verwendung einer Kombination aus Ethinylestradiol und Chlormadinonacetat zur Herstellung eines Arzneimittels
EP1655031A1 (de) 2004-10-08 2006-05-10 Schering AG Dienogest enthaltendes Langzeit-Verfahren zur Empfängnisverhütung
TW200727920A (en) * 2005-06-21 2007-08-01 Organon Nv New regimens for oral monophasic contraceptives
TW200744610A (en) * 2005-06-21 2007-12-16 Organon Nv New regimens for controlled drug delivery devices for contraception
US8153616B2 (en) 2005-10-17 2012-04-10 Bayer Pharma Aktiengesellschaft Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
DE102006003509A1 (de) * 2006-01-24 2007-07-26 Grünenthal GmbH Kontrazeptivum
EP1930010A1 (de) 2006-10-20 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido
GB0623813D0 (en) * 2006-11-29 2007-01-10 Stephenson Group Ltd Foam reduction
DE102007011486A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Arzneimittel umfassend wenigstens ein Gestagen
EP2140860A1 (en) * 2008-07-03 2010-01-06 Bayer Schering Pharma Oy An improved method of contraception
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CA2947767A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2365103C3 (de) * 1973-12-21 1980-08-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen V erwendung von Hormonen zur Kontrazeption
NL9301562A (nl) * 1993-09-09 1995-04-03 Saturnus Ag Preparaat voor substitutietherapie.
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
DE69532894T2 (de) * 1994-11-22 2004-09-02 Balance Pharmaceuticals, Inc., Pacific Palisades Verfahren zur empfängnisverhütung
DE19525017A1 (de) * 1995-06-28 1997-01-02 Schering Ag Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption
US5922349A (en) * 1995-09-28 1999-07-13 Schering Aktiengesellschaft Hormone replacement therapy method and hormone dispenser
NZ333750A (en) 1996-07-26 2000-09-29 American Home Prod Monophasic contraceptive method and kit comprising a combination of a progestin and estrogen
US5898032A (en) * 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy

Also Published As

Publication number Publication date
EP2153849A2 (en) 2010-02-17
TWI297271B (en) 2008-06-01
EP1317286B1 (en) 2009-11-11
AU2001284052B2 (en) 2006-11-30
CN1455681A (zh) 2003-11-12
CZ2003723A3 (cs) 2003-06-18
ME00291B (me) 2011-05-10
NO20031152L (no) 2003-05-14
ZA200301359B (en) 2004-02-05
DE60140462D1 (de) 2009-12-24
CA2420292A1 (en) 2002-03-21
JP2013006866A (ja) 2013-01-10
YU19003A (sh) 2006-05-25
BG111090A (bg) 2012-03-30
EA200300338A1 (ru) 2003-08-28
JP2013241456A (ja) 2013-12-05
KR20090033502A (ko) 2009-04-03
SK3102003A3 (en) 2003-09-11
CN100560132C (zh) 2009-11-18
WO2002022110A3 (en) 2002-07-04
KR20100056577A (ko) 2010-05-27
PE20020425A1 (es) 2002-06-15
BR0113902A (pt) 2003-07-22
KR101240232B1 (ko) 2013-03-07
EP2153849A3 (en) 2011-09-14
CA2420292C (en) 2010-12-14
MXPA03002070A (es) 2003-06-24
NO20031152D0 (no) 2003-03-13
EA006875B1 (ru) 2006-04-28
US20040219174A1 (en) 2004-11-04
UA93650C2 (ru) 2011-03-10
DE10045380A1 (de) 2002-04-04
IL154521A0 (en) 2003-09-17
MEP37608A (en) 2011-02-10
AU8405201A (en) 2002-03-26
IL154521A (en) 2014-05-28
WO2002022110A2 (en) 2002-03-21
BG107625A (bg) 2003-11-28
KR20030031185A (ko) 2003-04-18
US8536156B2 (en) 2013-09-17
PL361161A1 (en) 2004-09-20
HK1060305A1 (zh) 2004-08-06
HUP0301042A2 (hu) 2003-10-28
EE200300103A (et) 2005-02-15
US20120129823A1 (en) 2012-05-24
NZ524448A (en) 2005-03-24
ATE447972T1 (de) 2009-11-15
EP1317286A2 (en) 2003-06-11
US8076317B2 (en) 2011-12-13
HUP0301042A3 (en) 2010-03-29
UY26932A1 (es) 2001-12-28
HRP20030294A2 (en) 2005-02-28
JP2004508398A (ja) 2004-03-18

Similar Documents

Publication Publication Date Title
AR030737A1 (es) Metodo de anticoncepcion y forma de administracion del mismo
KR960706344A (ko) 호르몬 피임 및/또는 여드름 치료 수단 및 방법(means and method for hormonal contraception and/or the treatment of acne)
ES2190472T3 (es) Parche transdermico para la administracion de 17-deacetil norgestimato, solo o en combinacion con un estrogeno.
ES2087964T3 (es) Contraceptivos orales bajos en estrogenos.
PA8638601A1 (es) Regimenes y kits de progestina ciclica
AR005703A1 (es) Oxazolidinonas sustituidas, procedimiento para su preparacion, uso de las mismas para preparar medicamentos y medicamentos que las contienen
EA200201000A1 (ru) Гормон-заместительная терапия
DE60131850D1 (de) Hautpflegezusammensetzungen, die silikonelastomere enthalten
Unny et al. A review on potentiality of medicinal plants as the source of new contraceptive principles
SV2002000231A (es) Compuestos 2,4,-diaminopirimidina utiles como inmunosupresores ref. pc10547/20083/bb
NO986104L (no) Progesteron-anti-progesteron regimer
EA201200377A1 (ru) Способ пероральной контрацепции у женщин, способ управления нежелательными кровотечениями и предназначенная для применения в этих способах фармацевтическая упаковка
UY24308A1 (es) Tabletas exentas de aglutinante que contienen tramadol o una sal de tramadol, para administracion oral
FI964285A0 (fi) Taksaanien luokkaan kuuluviin johdannaisiin perustuvat farmaseuttiset valmisteet
NO20024646D0 (no) Kombinasjonsterapier med vaskul¶r-skadende aktivitet
BRPI0407652A (pt) método para acentuar a eficácia de um agente ativo, composição e método para produzir a composição
ES2165232T3 (es) Sistema terapeutico transdermico (tts) que contiene oxibutinina.
BRPI0509053A (pt) composição farmacêutica anidra e uso de um agente siliconado e de uma composição
AR043918A1 (es) Reduccion del crecimiento del vello utilizando una composicion que contiene difluorometilornitina
KR970061246A (ko) 테스토스테론을 증가시키기 위한 약학 조성물
ATE237331T1 (de) Deuterierte wirkstoffe in transdermaler applikation
AR036321A1 (es) Metodo y formulacion farmaceutica para el tratamiento de la discinesia de aparicion tardia.
NO20072893L (no) Fast, peroralt prevensjonsmiddel
CO5690602A2 (es) Regimenes anticonceptivos trifasicos extendidos
PE20011121A1 (es) Composicion farmaceutica que comprende un compuesto ciclico con un grupo sulfamato

Legal Events

Date Code Title Description
FA Abandonment or withdrawal